Lyophilizable and enhanced compacted nucleic acids
First Claim
Patent Images
1. A method of estimating the colloidal stability of a preparation of compacted nucleic acids, comprising the steps of:
- determining a turbidity parameter of a solution of compacted nucleic acid, wherein the turbidity parameter is defined as the slope of a straight line obtained by plotting log of apparent absorbance of light versus log of incident wavelength of the light, wherein said wavelength is between about 330 nm and 420 nm;
identifying the preparation as colloidally stable if a turbidity parameter of less than −
3 is determined and identifying the preparation as colloidally unstable if a turbidity parameter of greater than or equal to −
3 is determined.
1 Assignment
0 Petitions
Accused Products
Abstract
Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body. Moreover, counterions such as acetate can protect compacted nucleic acid complexes from adverse effects of lyophilization
168 Citations
176 Claims
-
1. A method of estimating the colloidal stability of a preparation of compacted nucleic acids, comprising the steps of:
-
determining a turbidity parameter of a solution of compacted nucleic acid, wherein the turbidity parameter is defined as the slope of a straight line obtained by plotting log of apparent absorbance of light versus log of incident wavelength of the light, wherein said wavelength is between about 330 nm and 420 nm;
identifying the preparation as colloidally stable if a turbidity parameter of less than −
3 is determined and identifying the preparation as colloidally unstable if a turbidity parameter of greater than or equal to −
3 is determined. - View Dependent Claims (117)
-
-
2. A non-naturally occurring composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said polycation molecules having a counterion selected from the group consisting of acetate, bicarbonate, and chloride, wherein said complex is compacted to a diameter which is less than (a) double the theoretical diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1:
- 1, in the form of a condensed sphere, or (b) 30 nm, whichever is larger.
- View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 47, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 133, 134, 135, 136, 137, 138, 139, 141, 142, 143, 144, 145, 146, 147, 149, 150, 151, 152, 153, 154, 156, 157, 158, 159, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)
-
20. A non-naturally occurring composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, wherein said polycation molecules have a counterion selected from the group consisting of acetate, bicarbonate, and chloride, said polycation molecule having a nucleic acid binding moiety through which it is complexed to the nucleic acid, wherein said nucleic acid molecule encodes at least one functional protein, wherein said complex is compacted to a diameter which is less than double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1:
- 1, in the form of a condensed sphere, or 30 nm, whichever is larger.
- View Dependent Claims (21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 69, 70, 71, 72, 73, 74, 75, 118, 132)
-
29. A non-naturally occurring composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single double-stranded cDNA molecule and one or more polycation molecules, said polycation molecules having a counterion selected from the group consisting of acetate, bicarbonate, and chloride, wherein said cDNA molecule encodes at least one functional protein, wherein said complex is compacted to a diameter which is less than double the theoretical minimum diameter of a complex of said single cDNA molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1:
- 1, in the form of a condensed sphere, or 30 nm, whichever is larger.
-
32. A non-naturally occurring composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said polycation molecules having a counterion selected from the group consisting of acetate, bicarbonate, and chloride, wherein said nucleic acid molecule encodes at least one antisense nucleic acid, wherein said complex is compacted to a diameter which is less than double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1:
- 1, in the form of a condensed sphere, or 30 nm, whichever is larger.
- View Dependent Claims (33, 34, 36, 37, 39, 40, 48, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 140, 148)
-
35. A non-naturally occurring composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said polycation molecule having a counterion selected from the group consisting of acetate, bicarbonate, and chloride, wherein said nucleic acid molecule is an RNA molecule, wherein said complex is compacted to a diameter which is less than double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1:
- 1, in the form of a condensed sphere, or 30 nm, whichever is larger.
-
38. A method of preparing a composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said method comprising:
mixing a nucleic acid molecule with a polycation molecule at a salt concentration sufficient for compaction of the complex to a diameter which is less than double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1;
1, in the form of a condensed sphere, or 30 nm, whichever is larger, whereby unaggregated nucleic acid complexes are formed, wherein each complex consists essentially of a single nucleic acid molecule and one or more polycation molecules, and wherein said polycation molecules have a counterion selected from the group consisting of bicarbonate and chloride.
-
41. A method of preparing a composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said method comprising:
mixing a nucleic acid molecule with a polycation molecule in a solvent to form a complex, said mixing being performed in the absence of added salt, whereby the nucleic acid forms soluble complexes with the polycation molecule without forming aggregates, wherein each complex consists essentially of a single nucleic acid molecule and one or more polycation molecules, wherein the complexes have a diameter which is less than double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1;
1, in the form of a condensed sphere, or 30 μ
m, whichever is larger, wherein the polycation has acetate as a counterion.- View Dependent Claims (42, 43, 49, 93, 94, 95, 96, 97, 155)
-
44. A method of preparing a composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said method comprising:
mixing a nucleic acid molecule with a polycation molecule in a solvent to form a complex, said mixing being performed in the absence of added salt, whereby the nucleic acid forms soluble complexes with the polycation molecule without forming aggregates, wherein each complex consists essentially of a single nucleic acid molecule and one or more polycation molecules, wherein the complexes have a diameter which is less than double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1;
1, in the form of a condensed sphere, or 30 nm, whichever is larger, wherein the polycation has a counterion selected from the group consisting of bicarbonate and chloride.- View Dependent Claims (45, 46, 50, 51, 52, 53, 54, 55, 56, 57, 58, 60, 61, 62, 63, 98, 99, 100, 101, 102)
-
59. A method of preventing or treating a disease or other clinical condition in a subject which comprises:
-
administering intramuscularly or to the lung of the subject a prophylactically or therapeutically effective amount of a composition comprising;
unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said polycation molecule having acetate as a counterion, wherein said complex is compacted to a diameter which is less than (a) double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1;
1, in the form of a condensed sphere, or (b) 30 nm, whichever is larger,said nucleic acid being one whose integration, hybridization or expression within target cells of said subject prevents or treats said disease or other clinical condition.
-
-
64. A method of preventing or treating a disease or other clinical condition in a subject which comprises:
administering intramuscularly or to the lung of the subject a prophylactically or therapeutically effective amount of a composition comprising;
unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said polycation molecule having a counterion selected from the group consisting of bicarbonate and chloride, wherein said complex is compacted to a diameter which is less than (a) double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1;
1, in the form of a condensed sphere, or (b) 30 μ
m, whichever is larger, said nucleic acid being one whose integration, hybridization or expression within target cells of said subject prevents or treats said disease or other clinical condition.- View Dependent Claims (65, 66, 67, 68)
- 103. A non-naturally occurring composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said polycation molecules having a counterion selected from the group consisting of acetate, bicarbonate, and chloride.
-
160. A method of preparing a composition comprising unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic acid molecule and one or more polycation molecules, said method comprising:
mixing a nucleic acid molecule with a polycation molecule at a salt concentration sufficient for compaction of the complex to a diameter which is less than double the theoretical minimum diameter of a complex of said single nucleic acid molecule and a sufficient number of polycation molecules to provide a charge ratio of about 1;
1, in the form of a condensed sphere, or 30 nm, whichever is larger, whereby unaggregated nucleic acid complexes are formed, wherein each complex consists essentially of a single nucleic acid molecule and one or more polycation molecules, and wherein said polycation molecules have a counterion selected from the group consisting of acetate, bicarbonate and chloride.
Specification